Human RCTPubMed ID: 34161837·2021

SURPASS-2: Tirzepatide with Metformin Background

Frías JP, Davies MJ, Rosenstock J, et al.

Diabetes Care, 2021 · n = 738

Key finding

Tirzepatide 15mg added to metformin reduced HbA1c by 2.1% versus 0.8% placebo (p<0.001); achieved 83% with A1c <7%.

Summary

Phase 3 trial of tirzepatide in patients already treated with metformin monotherapy.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

New England Journal of Medicine · 2024 · Human RCT

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

The Lancet · 2023 · Human RCT

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Nature Medicine · 2023 · Human RCT

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

New England Journal of Medicine · 2023 · Human RCT

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Sleep Medicine Reviews · 2023 · Human Pilot